$0.3593
-0.0148-3.96%
Last update: Nov 11, 7:36 PM
Heron Therapeutics Inc
HRTXNASDAQ
Heron Therapeutics fell 67.6% from $1.11 to $0.36, behind the S&P 500's +11.2%. Its worst day was Jun 2 (−45.6%), and its low came Sep 21 at $0.27.
Nov 12, 2025 – Nov 11, 2026 · picked from earnings, analyst actions, headlines and the biggest daily moves
Heron Therapeutics closed at its highest level of the year, 34.2% above where the year started.
+7.2% · S&P 500 +0.2%
EPS of $-0.02 beat the $-0.03 estimate on $40.6M revenue (est. $39.5M); FY revenue guidance of $173.0M–$183.0M against the $171.8M consensus.
Story events cover the past 12 months · Times ET
+11.1% · S&P 500 −0.6%
Heron Therapeutics shares rose 19.0%, while the S&P 500 rose 0.8%.
+19.0% · S&P 500 +0.8%
EPS of $-0.04 missed the $-0.02 estimate on $34.7M revenue (est. $36.6M); FY revenue guidance of $173.0M–$183.0M against the $174.8M consensus.
−21.0% · S&P 500 +0.2%
Heron Therapeutics shares fell 45.6%, while the S&P 500 rose 0.1%.
−45.6%, the year's worst day · S&P 500 +0.1%
EPS of $-0.03 missed the $-0.02 estimate on $37.7M revenue (est. $42.2M).
−31.7% · S&P 500 0.0%
Heron Therapeutics closed at its lowest level of the year, 75.7% below where the year started.
−12.8% · S&P 500 +1.6%
Heron Therapeutics shares rose 15.9%, while the S&P 500 fell 0.2%.
+15.9% · S&P 500 −0.2%
EPS of $-0.03 beat the $-0.03 estimate on $35.3M revenue (est. $37.5M).
+26.5%, the year's best day, on 139M shares, the year's heaviest volume · S&P 500 +2.4%
Where it ended: a close of $0.36 on Nov 11, 2026. Up next: Q4 2026 earnings on Feb 25, 2027 (EPS est. $-0.02, revenue est. $33.0M).
Nothing in the past 12 months.
All HRTX dividend historyReplay the year: the line draws itself and stops at each of the 9 moments with what happened and how the stock reacted.
Chart by ChartIQ. Events, ratings, quote and fundamentals from Benzinga APIs. Daily bars for HRTX and SPY from Benzinga historical bars. Not investment advice.
